Absolute bioavailability and safety of a novel rivastigmine nasal spray in healthy elderly individuals.

ABSTRACT:

Aims

To test the feasibility of a novel rivastigmine nasal spray as prospective treatment for dementia.

Methods

A single dose, crossover absolute bioavailability and safety study was conducted with rivastigmine intravenous solution (1 mg) and nasal spray (3.126 mg) in eight healthy elderly individuals, aged 58-75 years.

Results

Absolute bioavailability (F) of the nasal spray was significant at 0.62 (0.15) for F > 0 (P < 0.001, n = 8). The systemic dose absorbed was 2.0 (0.6) mg, time to maximum plasma concentration was 1.1 (0.5) h and maximum plasma concentration was 6.9 (2.0) ng ml^-1 . The NAP226-90 to rivastigmine AUC_0-∞ ratio was 0.78 (0.19). The single dose safety was good with two of five mild adverse events related to the nasal spray. Nasal

SUBMITTER: Morgan TM 

PROVIDER: S-EPMC5306491 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature